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ABSTRACT
Background: Evidence-based smoking cessation guide-
lines recommend nicotine replacement therapy (NRT),
bupropion SR and varenicline as first-line therapy in
combination with behavioural interventions. However,
there are limited data to guide clinicians in recommending
one form over another, using combinations, or matching
individual smokers to particular forms.
Objective: To develop decision rules for clinicians to
guide differential prescribing practices and tailoring of
pharmacotherapy for smoking cessation.
Methods: A Delphi approach was used to build
consensus among a panel of 37 international experts from
various health disciplines. Through an iterative process,
panellists responded to three rounds of questionnaires.
Participants identified and ranked ‘‘best practices’’ used
by them to tailor pharmacotherapy to aid smoking
cessation. An independent panel of 10 experts provided
cross-validation of findings.
Results: There was a 100% response rate to all three
rounds. A high level of consensus was achieved in
determining the most important priorities: (1) factors to
consider in prescribing pharmacotherapy: evidence,
patient preference, patient experience; (2) combinations
based on: failed attempt with monotherapy, patients with
breakthrough cravings, level of tobacco dependence; (3)
specific combinations, main categories: (a) two or more
forms of NRT, (b) bupropion + form of NRT; (4) specific
combinations, subcategories: (1a) patch + gum, (1b)
patch + inhaler, (1c) patch + lozenge; (2a) bupropion +
patch, (2b) bupropion + gum; (5) impact of comorbidities
on selection of pharmacotherapy: contraindications,
specific pharmacotherapy useful for certain comorbidities,
dual purpose medications; (6) frequency of monitoring
determined by patient needs and type of pharmacother-
apy.
Conclusion: An algorithm and guide were developed to
assist clinicians in prescribing pharmacotherapy for
smoking cessation. There appears to be good justification
for ‘‘off-label’’ use such as higher doses of NRT or
combination therapy in certain circumstances. This
practical tool reflects best evidence to date of experts in
tobacco cessation.
Helping smokers quit is a critical, yet often
perplexing role for physicians. While pharma-
cotherapy generally doubles the odds of quitting
successfully, these smoking cessation aids are not
widely prescribed or used by smokers.
12Although
guidelines exist in several countries (United States,
United Kingdom, France, Australia, New
Zealand)
3–8 that recommend nicotine replacement
therapy (NRT) or bupropion SR as first-line
medication, limited data are available to guide
clinicians in selecting specific forms of pharma-
cotherapy for individual smokers. While vareni-
cline, a new pharmacotherapeutic option, has
demonstrated therapeutic superiority over existing
first-line medications,
9–12 post-marketing reviews
have recently raised safety concerns regarding
varenicline.
13
The health benefits of smoking cessation are
well documented. Smokers who quit reduce their
risk of cardiovascular disease, lung disease, and
cancer and increase their life expectancy substan-
tially.
14 While most smokers make several quit
attempts before they succeed, about one in four
who use any pharmacotherapy will eventually quit
smoking.
15 Evidence indicates that pharmacother-
apy increases the odds of success and may reduce
symptoms of withdrawal for those who smoke 10
or more cigarettes per day.
81 5While a few studies
have shown that pharmacotherapy works even in
the absence of psychosocial therapies,
16 17 most
studies show that combining pharmacotherapy
and psychosocial treatments increases quit rates.
38
A Cochrane review
16 including 123 trials con-
cluded that all types of NRT increased the odds of
quitting by approximately one-and-a-half to two-
fold. In addition, the effectiveness of NRT was
independent of the intensity of behavioural sup-
port provided to the smoker. Bupropion SR and
nortriptyline (antidepressants) were found to
increase rates of smoking cessation in a Cochrane
review of antidepressants including 53 trials.
18
When prescribed as monotherapy, bupropion (31
trials) and nortriptyline (four trials) both doubled
the odds of cessation. Bupropion and nortriptyline
appear to have similar effectiveness to NRT. Other
antidepressants (fluoxetine, sertraline, paroxetine,
moclobemide, venlafaxine) have not shown sig-
nificant benefit as an aid to smoking cessation.
18
While studies of rimonabant have been com-
pleted,
19 no reviews currently exist and there have
been conflicting results regarding its efficacy in the
US and Europe.
20 21
Clonidine (an a-adrenergic antagonist) was
found to be an effective medication for smoking
cessation, although findings were based on a small
number of trials.
22 Studies on other types of
pharmacotherapy for smoking cessation are lim-
ited. Cochrane reviews have been conducted on
anxiolytics,
23 silver acetate,
24 lobeline,
25 mecamyl-
amine
26 and naltrexone,
27 but findings are incon-
clusive owing to insufficient studies.
Varenicline, an a4 b2 nicotine receptor partial
agonist, is the newest pharmacotherapy indicated
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maintaining moderate levels of dopamine to counteract with-
drawal symptoms and by reducing smoking satisfaction.
28
Developed in 1997, it was approved in 2006 by the American
Food and Drug Administration under the trade name Chantix,
and by the European Medicines Evaluation Agency under the
trade name Champix.
In the most recent Cochrane review, Cahill and colleagues
28
found that varenicline ‘‘increased the chances of successful long-
term smoking cessation between two- and threefold compared
with pharmacologically unassisted quit attempts.’’ However,
physicians prescribing varenicline need to be aware of the
possible association with behavioural changes such as depressed
mood, agitation and suicidal thoughts and behaviours. The US
Food and Drug Administration recently issued a public health
advisory, cautioning that there may be an increased risk of
neuropsychiatric symptoms among patients taking vareni-
cline.
13 It is important to note that these symptoms may also
arise as a result of smoking cessation with or without
treatment, and causality has not yet been determined. The
FDA is currently conducting a safety review. In particular, the
safety and efficacy of varenicline in patients with psychiatric
disorders is unknown (this population was excluded from pre-
marketing trials). While an initial study in the UK (204 patients
on NRT; 208 on varenicline) found no evidence that varenicline
exacerbated mental illness,
29 several individual case studies have
been cited in the literature that report adverse psychiatric
symptoms.
30–34 The labelling of varenicline has now been
changed to include warnings regarding adverse effects and
stating that smokers considering use of varenicline should be
screened for a history of psychiatric disorder and monitored
closely for psychiatric adverse events.
35 Clearly, ‘‘there is a need
for individual community-based trials of varenicline, to test its
efficacy and safety in smokers with varying comorbidities and
risk patterns.’’
28
Although seven first-line types of pharmacotherapy (bupro-
pion,nicotine gum, nicotine inhaler, nicotine lozenge, nicotine
nasal spray, nicotine patch and varenicline) are recommended
by the US Public Health Service Clinical Practice Guideline,
36
there is no guidance on how to select a particular form of
pharmacotherapy (or combination of pharmacotherapy) that
will be most useful for individual patients. LeFoll and George
37
report that ‘‘no clear threshold exists that can help clinicians
decide whether a patient will benefit from a particular
pharmacotherapy, and there is no consensus on which type of
pharmacotherapy should be used first’’. Few studies have been
conducted combining different medications for increasing
smoking cessation rates.
38
Hughes and colleagues
39 suggest that ‘‘studies simply showing
that new treatments are more effective than placebo need to be
supplemented by studies comparing treatments or testing
patient-treatment matching theories’’. Thus, clinicians are faced
with the problem of selecting pharmacotherapy for patients
with insufficient information and diverse opinions. They must
rely solely on patient preference and past experience or on
clinician familiarity with particular pharmacotherapy. This is a
challenge that clinicians face on a daily basis.
When empirical evidence is inadequate, consensus methods
can provide a vital component to synthesising knowledge.
Consensus methods are particularly useful when dealing with
conditions of uncertainty, insufficient data and incomplete
theory.
40 41 A consensus method that has been widely used in
health research is the Delphi approach. Delphi is a structured,
systematic method using an iterative process to build consensus
among a panel of experts.
42 43 It is a powerful tool for making
the best use of less than perfect information. The Delphi
consists of a multistage approach with each stage building on
the results of the previous one. It allows for collecting and
refining combined knowledge and experience from a group of
experts from various disciplines. This approach has been used
effectively by the investigators in a knowledge synthesis of
smoking cessation among employed and unemployed young
adults.
44
The aim of this study was to develop decision rules
(algorithm) for use by clinicians to guide prescribing practices
of pharmacotherapy for smoking cessation. Experts in smoking
cessation were recruited from 13 countries to participate in a
Delphi consensus-building process. The results were synthesised
into a clinical aid that can be widely used by clinicians who
prescribe pharmacotherapy to smokers.
METHODS
Study design
A modified Delphi method was employed to identify and rank
‘‘best practices’’ used by healthcare practitioners in tailoring
prescribing practices of pharmacotherapy to aid smoking
cessation. Three Delphi rounds were conducted from May to
September 2007, using primarily email communication. Thirty-
seven panel members participated through an iterative process,
responding anonymously to a series of questionnaires.
Anonymity was intended to minimise ‘‘peer pressure’’ and
enhance the free flow of ideas. Questions focused on how
practitioners make decisions regarding selection of specific
forms (or combination of forms) of pharmacotherapy for
individual smokers. Also addressed was frequency of monitoring
and follow-up, as well as the impact of medical or psychiatric
comorbidities on pharmacotherapy selection.
Expert panel
Experts were identified by an extensive search of the literature
for their publications, keynote speakers on pharmacotherapy
and smoking cessation at conferences, and by recommendations
of the authors and other colleagues in the field. Seventy-three
experts were invited to participate, with a 51% (37 out of 73)
response rate. A deliberate effort was made to balance the panel
with respect to gender, knowledge areas and geographic
distribution. The panel comprised health practitioners (physi-
cians, pharmacists) and researchers from 13 countries: 9 from
Canada, 15 from the US and 13 from other countries including,
Australia, Czech Republic, France, Greece, Netherlands, New
Zealand, Norway, Russia, Spain, Sweden and Switzerland.
Participants were involved in various types of practice:
specialised smoking cessation, family practice, specialised
practice (internal medicine, pulmonology), hospital-based
(non-addiction or smoking cessation specific), addictions,
mental health, academic (medical schools) and public health.
Twenty-nine panellists were male; eight were female. Informed
consent was obtained before the start of round 1. Participants
were offered a small honorarium of $150 for completing the
three rounds. Confidentiality of individual opinions of the
panellists was maintained throughout the study (except to
researchers). All findings represent the collective opinion of the
panel. The research ethics board at the Centre for Addiction and
Mental Health (CAMH) ruled that a formal review of the study
protocol was not necessary, because the study participants were
health experts and not at risk.
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The goal was to generate ideas and identify important
priorities in prescribing or recommending pharmacotherapy
for smoking cessation. Pilot testing of the questions was
conducted with a small group of experts to ensure that the
questions were clear. Panellists were asked to respond to four
open-ended questions:
1. What factors do you consider in deciding which particular
form of pharmacotherapy to prescribe or recommend?
2. Have you prescribed or recommended combinations of
pharmacotherapy?Ifyes,forwhichtypeofpatient?Describe.
3. What is the impact of medical or psychiatric comorbidities
on your selection of pharmacotherapy?
4. What is your usual practice regarding frequency of
monitoring patients while using pharmacotherapy?
5. In response to the first four questions, panellists generated
a list of priorities and provided comments to support their
suggestions.
Round 2
The goal was to identify priorities for each of the first four
questions, with the content derived from the results of round 1.
Content analysis was used to identify the major themes
generated from the four central questions (and parts to
questions) from round 1. Nine lists of priorities were produced
and panellists were then asked to review and rank the items on
Table 1 Level of agreement by question and priority item
Priority No Questions and priority items
Agreement
Number out of 37 %
1. Factors considered in prescribing pharmacotherapy(ies)
1 Evidence 32 86
2 Patient preference 30 81
3 Patient experience 29 78
4 Patient needs 28 76
5 Patient history 27 73
6 Patient’s clinical suitability 28 76
7 Potential drug interactions/side effects 28 76
Mean 29 78
Kendall’s W (coefficient of concordance) 0.68
Statistical significance p,0.001
First principal component 79.4% of variance
2. Combinations of pharmacotherapies prescribed based on
1 Failed attempt with monotherapy 30 81
2 Patients with breakthrough cravings 30 81
3 Level of dependence 27 73
4 Multiple failed attempts 31 84
5 Patients with nicotine withdrawal 31 84
Mean 29 78
Kendall’s W (coefficient of concordance) 0.70
Statistical significance p,0.001
First principal component 78.6% of variance
3. Specific combinations of pharmacotherapies: main categories
1 Two or more forms of NRT 34 92
2 Bupropion + form of NRT 34 92
Mean 34 92
4. Specific combinations of pharmacotherapies: subcategories
2 or more forms of NRT
1 Patch + gum 34 92
2 Patch + inhaler 32 86
3 Patch + lozenge 32 86
Mean 33 88
Bupropion + form of NRT
1 Bupropion + patch 33 89
2 Bupropion + gum 33 89
Mean 33 89
5. Impact of comorbities on the selection of pharmacotherapy(ies)
1 Contraindications 36 97
2 Specific pharmacotherapies useful for certain comorbidities 36 97
3 Dual purpose medications 36 97
Mean 36 97
6. Frequency of monitoring determined by
1 Patient needs 36 97
2 Type of pharmacotherapy 36 97
Mean 36 97
Research paper
36 Tobacco Control 2009;18:34–42. doi:10.1136/tc.2008.025635each list. In addition, they were asked to provide reasons for
their top choices in each category.
Round 3
The goal was to consolidate consensus. After scoring the
responses from round 2, the top priorities were obtained for six
key categories. A list of these priorities, as well as a brief
summary of comments for each, was distributed to the
panellists. The number of priorities for each category was
chosen based on where there was a clear and distinct drop in
priority scores. Consensus was consolidated as panellists were
asked to either agree with the rankings or re-rank their choices
for each category. They were asked to provide an explanation
for any rankings with which they disagreed.
Statistical analyses
Kendall’s W statistic and a principal components analysis (Q
technique)
45 46 were computed, using SPSS software version 15,
for the first two questions. This was not done on the remaining
four questions because of the extremely high level of agreement.
Figure 1 Algorithm for tailoring
pharmacotherapy for smoking
cessation*{
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the level of agreement among raters with the overall ranking of
items. This is a fairly conservative test regarding concordance
because it considers the degree to which raters rank all priorities
in a given question in exactly the same order. For example, in
question 1 (factors considered in prescribing pharmacotherapy),
Kendall’s W assesses the degree to which each rater ranked the
seven priorities in identical order.
A principal components analysis (Q technique) was con-
ducted on the correlation matrix among raters with each other.
A very large first principal component (% variance) indicates
that the raters are forming a single cluster (factor) or
perspective, rather than distinct subgroups (factors) that would
be evident if the variance was more distributed across the first
few principal components.
RESULTS
All 37 members (100%) of the panel completed the entire
process. After three Delphi rounds, the panel members reached a
high level of consensus in determining the most important
priorities for prescribing and recommending pharmacotherapy
for smoking cessation.
Round 1
Responses from four open-ended questions posed in round 1
were analysed and categorised according to common themes to
generate nine lists of priorities (appendix I available from
corresponding author). Explanations and examples given by
panellists were also summarised and included.
Round 2
The nine lists of priorities (together with a summary of
comments) were sent to panel members. They were asked to
rank all items on each list and to provide reasons for their top
choices. Then, their rankings were combined to produce a total
score for each priority (for example, for a list of 10 items, the
first or highest ranked item = 10 points, second=9 points …
10th=1 point). The results are given in appendix II (available
from corresponding author). The number of priorities was based
on where there was a clear and distinct drop in score.
Round 3
In this final consensus-building round, scores were calculated to
generate priorities for the six questions. These priorities, and a
summary of comments for each, were sent to panel members
who were asked to either agree or disagree with the rankings.
They were also requested to provide explanations for any
disagreement with a ranking. Comments provided by panellists
during all three rounds were analysed for content and major
themes.
The results in table 1 show a high degree of consensus on the
most important priorities for prescribing pharmacotherapy for
smoking cessation. Percentage of agreement was calculated by
summing the number of raters who agreed with the factor
divided by the total number of raters (x 100). The average
agreement with the six questions was 84%. Agreement with
specific items in each category, ranged from 73% to 97%.
Question 1: Factors considered in prescribing pharmacotherapy
Kendall’s W coefficient of concordance was 0.68, which was
statistically significant at p,0.001. The high level of con-
cordance was further evidenced by the first principal compo-
nent (79.3%), accounting for almost 80% of the variance among
raters. This underscores that the raters largely agreed on the
ranking of items for question 1. The highest levels of agreement
are with the top three items: (1) evidence, 86%; (2) patient
preference, 81%; and (3) patient experience, 78%.
Question 2: Combinations of pharmacotherapy
Kendall’s W coefficient of concordance was 0.70, which was
statistically significant at p,0.001. The high level of con-
cordance was further evidenced by the first principal compo-
nent accounting for 78.6% of the variance among raters.
Interestingly, the highest levels of agreement were with the
lower ranked items, (4) and (5): (4) Multiple failed attempts,
84%; (5) Patients with nicotine withdrawal, 84%. Agreement
with the first two items was also high: (1) Failed attempt with
monotherapy, 81%; (2) Patients with breakthrough cravings,
81%. There was least agreement on the middle ranked item (3)
Level of dependence, at 73%.
Question 3: Specific combinations of pharmacotherapy, main
categories
Overall level of agreement of priorities for specific pharma-
cotherapies was particularly high at 92%.
Question 4: Specific combinations of pharmacotherapy,
subcategories
There was high overall agreement (81%) of the priorities for
subcategories of pharmacotherapies under the main categories
identified in question 3. The highest level of agreement was
item (1) under two or more forms of NRT, patch + gum, at 92%.
Bupropion + patch and bupropion + gum were also compelling
at 89%.
Question 5: Impact of comorbidities
Ninety-five per cent (36 out of 37 panelists) agreed with the
specific rankings for this question.
Question 6: Frequency of monitoring
Overall agreement (97%) was significantly high for this
question—only one panelist disagreed with the ranking of
items.
An important addition to this study was an independent panel
of 10 international experts (two from Canada, three from the
US, two from the UK, one from Denmark, one from France and
one from Poland) to provide external validation of our findings.
The final rankings of the original panel were sent to the
independent panel by email, at the completion of round 3. They
were asked to agree or disagree with the rankings for the six
categories. Also, they were asked to re-rank any priorities with
which they disagreed and to provide an explanation for their
choice.
The level of agreement with priority rankings for each
question between the independent panel and the original panel
was quantified. The results of the independent panel rankings
showed a high degree of congruence with the rankings of the
original Delphi panel. The average agreement with the six
questions was 87%. Agreement with specific items in each
category, ranged from 70% to 100%. For question 1, the level of
agreement was 74%; question 2, 74%; question 3, 100%;
question 4, 84%, question 5, 100% and question 6, 90%.
Algorithm
An algorithm to guide decision-making regarding pharmacother-
apy for smoking cessation is given in figure 1. This algorithm
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Factors to consider in prescribing pharmacotherapy
Three distinct types of pharmacotherapy have demonstrated efficacy for smoking cessation: (a) nicotine replacement therapy
(including patch, gum, inhaler, lozenge, nasal spray), (b) bupropion and (c) varenicline (for a description of these pharmacotherapy,
including dose and side effects/drug interactions, see table 3). Selecting a particular type of pharmacotherapy should be guided by
the following seven factors:
1. Evidence
The importance of evidence-based medicine is the top priority in considering which form of pharmacotherapy to prescribe or
recommend to a patient. The decision to prescribe smoking cessation medications needs to be based on evidence of effectiveness
and safety (see Fiore et al
36).
2. Patient preference
Patient preference is an important priority in facilitating adherence to the treatment protocol. There is no value in prescribing or
recommending a medication that a patient will not take. ‘‘It is essential that the patient be comfortable with the decision, have
reasonable expectations for product efficacy, and have confidence in their ability to use the medication appropriately’’. Preference is
particularly important if a patient does not want to use a specific product. However, patient preference can be modified through an
informed and shared decision-making process between the clinician and patient.
3. Patient experience
The patient’s expectation of success is exceedingly important in determining actual success. Expectations are often informed by
experience. Therefore, a patient’s experience with smoking cessation attempts and use of pharmacotherapy needs to be a
significant factor in influencing choice of pharmacotherapy. ‘‘A clinician must understand what the patient has tried and why the
patient did not succeed’’. If the patient was successful with a particular medication for a period of time, it may be prudent to try the
same medication again; if unsuccessful with a particular medication, then probably should not use again.
4. Patient needs
Because there is little evidence-based information to guide tailoring of specific pharmacotherapy to specific patients, patient needs
are vital. Consideration of patient needs is important in determining their willingness to use medications, the ease of use of various
smoking cessation products and likelihood of compliance. Other patient needs to take into account before prescribing or
recommending a particular pharmacotherapy include: extent and severity of cravings, situations or times when cravings are
strongest, triggers for smoking, specific hurdles to overcome, etc.
5. Patient history
‘‘Patient history provides the framework within which I can prescribe’’. Many patients have comorbidities (medical, psychiatric,
alcohol/drug abuse) which need to be taken into account. For example, a patient with a history of alcohol abuse or seizures would be
excluded from bupropion use. Smoking history, past quit attempts and experience with pharmacotherapy are all factors influencing
the decision of pharmacotherapy choice.
6. Patient clinical suitability for pharmacotherapy
Some patients may not be suitable for pharmacotherapy interventions and potential contraindications need to be considered.
Generally, pharmacotherapy would not be recommended for patients having a low level of nicotine dependence. In addition, a
patient may prefer a non-pharmacological approach to treatment.
7. Potential drug interactions/side effects
Issues of safety are fundamental in determining choice of pharmacotherapy. Contraindications, use of other medications, and the
side effect profile all need to be considered. However, this is generally a minor problem with cessation drugs. ‘‘Potential drug
interactions are a show-stopper when it is relevant, but it is rarely an issue, so it is important but infrequent’’.
Combinations of pharmacotherapy
For some patients, choosing a combination of pharmacotherapy will increase their ability to stop smoking. Combination
pharmacotherapy is indicated for patients based on five factors:
1. Failed attempt with monotherapy
Use of monotherapy which resulted in a failure to quit smoking is the top priority when considering use of combination
pharmacotherapy. The general principle is that intensity of medications should be increased when monotherapy has resulted in
relapse. A caveat is that the medication was used appropriately and that there was ‘‘a ‘true’ attempt to quit’’.
2. Patients with breakthrough cravings
Breakthrough cravings may be an indication that more treatment is needed. An additional form of NRT or an addition of NRT (as
needed) to a non-NRT oral medication may be helpful. Combinations of NRT can be used for steady-state delivery (patch) and as
needed (gum/lozenge).
3. Level of dependence
Highly dependent smokers are more likely to benefit from combination pharmacotherapy. It may be important to begin with
combination pharmacotherapy for these individuals. Because this group has a difficult time in quitting smoking, combination therapy
may facilitate increased success.
4. Multiple failed attempts
Multiple failed attempts may be an indication that more intensive therapy is needed. ‘‘Careful assessment of previous attempts
usually reveals complex situations which are more likely to be addressed with combination pharmacotherapy.’’ However, it is
important to keep in mind that failed attempts may also be based on patient lack of commitment rather than insufficient medication.
5. Patients with nicotine withdrawal
Patients experiencing nicotine withdrawal can be a trigger for their relapse to smoking. The combination of pharmacotherapies (for
example, addition of NRT to another pharmacotherapy) can be a helpful response for managing nicotine withdrawal symptoms.
Specific combinations of pharmacotherapy
When prescribing or recommending combinations of pharmacotherapy, first select combinations of NRT. Then, prescribe a
combination of bupropion and NRT for more heavily dependent patients.
1. Two more forms of NRT
The use of two or more forms of NRT has the strongest evidence base and is the most commonly used form of combination therapy.
There is a high level of confidence that this combination can be used safely and effectively. ‘‘This approach permits optimal titration
of NRT to meet nicotine needs and can be achieved easily and cheaply’’.
2. Bupropion + form of NRT
Continued
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and extends algorithms developed by Selby
47 and published in a
paper by LeFoll and George
37 and the one developed by
Hughes,
48 by specifying how to select a specific type or
combination of pharmacotherapy (fig 1). A guide for using the
algorithm was developed from the comments of the panel
members (table 2). Table 3 provides a description of types of
pharmacotherapy used for smoking cessation.
DISCUSSION
The Delphi, based on well-researched principles, is a widely
accepted method used in studies ranging from technology
forecasting to drug abuse.
49 It is a powerful tool for making the
best use of less than perfect information. It should be noted that
the existence of consensus from a Delphi process does not mean
that the ‘‘correct’’ answer has been found. However, this
process does aim to ‘‘negotiate a reality that can then be useful
in moving a particular field forward, planning for the future or
even changing the future by forecasting its events.’’
50
The consensus view in this study offers practical and realistic
guidance to clinicians. It reflects the best evidence to date of
expert views in the tobacco cessation field. Participants were
enthusiastic about the topic, evidenced by 100% participation in
all three rounds. Achieving a 100% response rate is rare in a
Delphi process. This method asks much more of respondents
than a single survey and the potential for low response rates
increases exponentially with each round. This high response
rate was the result of the participants’ fervent interest in the
topic and the investigators’ strategy to improve follow-up. The
use of an independent panel is an innovative addition to
standard Delphi methodology. The high level of agreement of
the independent panel with the consensus achieved by the
original panel strengthens the credibility of our findings.
Cost of smoking cessation medications can be a key concern
since all available pharmacotherapy treatments are relatively
expensive. However, cost varies across countries, from free
provision to insurance coverage to full payment required by
patients. While cost was listed as a concern by experts in round
1 of the Delphi process, it did not emerge as a top priority from
the clinician’s perspective. If focus groups had been conducted
with smokers, it may have emerged as a greater priority.
44
The algorithm developed from this study (fig 1) provides a
practical tool for clinicians. This reflects the current approach of
experts in smoking cessation and may serve as a guide for
practitioners. It also adds value to current knowledge and
existing algorithms
37 47 48 by prioritising factors to consider in
prescribing pharmacotherapy. The expert comments sum-
marised in table 2 serve as a guide for training and using the
algorithm.
A major strength of this study is the international panel.
However, a limitation in that not all panellists have equal access
to the range of pharmacotherapy reviewed. At the time of this
study, varenicline was just being introduced into many
jurisdictions. Therefore, experts may not have been as familiar
with it. Given the limited availability of varenicline and recent
safety concerns, this algorithm may need to be updated in the
future. Although varenicline has demonstrated clear evidence of
efficacy in smoking cessation, it is essential to consider the
safety concerns and risks recently raised by the FDA. Smokers
considering use of varenicline should be screened for a history of
psychiatric disorders, have close monitoring, and be advised to
report any adverse effects they might experience. Particular care
and monitoring need to be taken if prescribing to patients with
psychiatric disorders.
There was not an exhaustive representation of experts by
countries. Although desirable, this was beyond the scope and
means of this study. Data were collected from the Delphi panel
members regarding potential conflicts of interest. Twenty-four
of the 37 panellists indicated that they have received some
funding from the pharmaceutical industry (details are available
from the corresponding author). However, panel members with
potential conflicts of interest did not respond differently from
those who had no conflicts. Therefore, this did not appear to
affect our recommendations.
Table 2 Continued
Bupropion plus a form of NRT can be effective for some patients. This combination is generally used in more heavily dependent
patients.
Impact of comorbidities on selection of pharmacotherapy
When prescribing pharmacotherapy to patients having a dual diagnosis (that is, medical, psychiatric or other substance use in
addition to smoking), specific attention should be given to:
1. Contraindications
Attention to contraindications is the top priority in the selection of type of pharmacotherapy in patients with comorbidities. Ensuring
the safety of a patient is always of primary importance in prescribing or recommending medications. Contraindications are primarily
an issue with use of bupropion (that is, history of seizures, alcohol problems) and with patients who are already taking other
medications.
2. Specific pharmacotherapy useful for certain comorbidities
Specific pharmacotherapy may be useful for treatment of certain comorbidities in addition to smoking cessation. For example,
bupropion may be a good choice for depressed patients who want to quit smoking. However, for patients with anxiety disorders or
eating disorders, bupropion would not be a good choice.
3. Dual purpose medications
‘‘It’s nice to treat two things with one med so if I can do that I will’’. Most common is use of bupropion for depressed patients who
want to quit smoking. Bupropion can also be useful for patients who do not want to gain weight. Dual purpose medications may
have added value in enhancing compliance.
Frequency of monitoring
All patients taking pharmacotherapy should be monitored carefully. The frequency of monitoring should be determined by:
1. Patient need
The top priority for frequency of monitoring should be determined by patient needs. For example, patients with multiple or difficult
quit attempts will likely require more support.
2. Type of pharmacotherapy
Some types of pharmacotherapy may require more frequent monitoring, particularly if there is potential for adverse events (for
example, drug interaction, side effects).
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The Delphi panel of 37 experts clearly recognised the wide gap
in the smoking cessation literature regarding effective prescrib-
ing practices. Our study addressed this gap by achieving a high
level of consensus on priorities in prescribing pharmacotherapy.
The validation by an independent expert group provides further
assurance. The algorithm (fig 1), guide (table 2) and pharma-
cotherapy description (table 3) can assist healthcare practi-
tioners in the art of prescribing pharmacotherapy for smoking
cessation. These clinical aids will hopefully engage and assist a
larger number of clinicians to incorporate smoking cessation
interventions in their practice.
A defining characteristic of tobacco control—most likely a
necessary one—is that action has typically preceded a strong
body of research understanding. Knowledge has derived from
analysis of that experience.
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Table 3 Pharmacotherapy used for smoking cessation
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Drug Dose Side effects/drug interactions Comments
NRT: sustained release
Nicotine transdermal patch
(Habitrol, Nicoderm,
generics)
.20 cigarettes/day: 1 patch (21 mg/24 h) for
4–6 weeks, then taper to 14 mg/day for 2–4
weeks, then 7 mg per day for 2–4 weeks.
If patient has cardiovascular disease, weighs
less than 45 kg or smokes ,K pack/day begin
with 14 mg/24 h66 weeks then Q to 7 mg/24 h
62 weeks
NB: 16-h patches are available in some countries
Side effects:
Skin sensitivity and irritation (most common);
abnormal dreams; insomnia; nausea, dyspepsia
Start patch on quit date. Advise not to smoke
cigarettes while using the patch, though this is
generally safe and does not indicate treatment
failure. Educate users on the signs and
symptoms of nicotine toxicity
NRT: immediate release
Nicorette inhaler (nicotine
inhaler)
Available in 4 mg strength.
Encourage patient to use at least six doses/day
for the ?rst 3–6 weeks.
Max 12/day.
Tapering: gradual reduction in use over next
6–12 weeks, stopping when reduced to 1–2/day
Side effects:
Mild local irritation of mouth and throat,
coughing, rhinitis that may decline with
continued use
Not a true inhaler—the nicotine is delivered
and absorbed buccally.
‘‘Hand-mouth’’ activity from using the inhaler is
preferred by some quitters while others ?nd it
to be a trigger. Useful in those with poor oral
health or dentures and in those who cannot
chew gum
NRT: immediate release
Nicotine polacrilex gum
(Nicorette Gum)
10–12 pieces per day initially (2 mg or 4 mg
pieces) to maximum of 20 pieces per day, for
12 weeks.
Tapering: 1 piece/day each week, as withdrawal
symptoms allow
Side effects:
Mouth soreness, hiccups, dyspepsia, jaw ache
Use 4 mg in heavily dependent smokers. May
be used for temporary abstinence—eg, to
comply with smoking restrictions on aeroplanes
NRT: immediate release
Nicotine lozenge
1 lozenge (2 mg or 4 mg lozenges) every 1–2 h
up to 6 weeks; weeks 7–9, every 2–4 h; weeks
10–12, every 4–8 h
Side effects:
Nausea, hiccups, heartburn, headache, coughing
NRT: immediate release
Nicotine nasal spray
1.0 mg of nicotine per spray (10-ml bottle
contains 100 mg nicotine) 1–2 doses/h up to
40 doses per day; for 3 months
Side effects:
Mild nasal/throat irritation
Antidepressant:
Bupropion (Zyban, generics)
150 mg daily 63 days then 150 mg twice daily
67–12 weeks. Begin 1–2 weeks before the
selected quit date
Side effects:
Insomnia, dry mouth
Drug interactions:
Clearance of bupropion may be Q by inhibitors
(for example, ticlopidine) or q by inducers (for
example, phenobarbital, phenytoin, primidone) of
CYP2B6. May Q clearance of other substrates
of CYP2B6 (for example, cyclophosphamide,
ketamine, promethazine, propofol, selegiline).
MAOIs, levodopa, amantadine may q toxicity.
May be safely combined with NRT (monitor for
treatment-emergent hypertension)
Not recommended in patients with conditions
predisposing to seizures, history of seizures,
current eating disorder or severe hepatic
impairment.
Least expensive of oral medications indicated
for smoking cessation
Nicotine receptor partial
agonists
Varenicline (Champix,
Chantix)
0.5 mg daily for 3 days, then twice daily for
4 days then 1 mg by mouth twice daily for
12 weeks.
Patient should quit smoking 1–2 weeks after
starting the medication. Reassess if patient is
still smoking 4 weeks after starting medication;
can be continued for an additional 12 weeks if
patient has bene?ted. No tapering necessary
Side effects: nausea, sleep disturbance,
abnormal/vivid/strange dreams.
Drug interactions: should not be combined with
NRT therapy because of increased risk of
adverse effects
Does not induce cytochrome P450 enzymes;
excreted renally unchanged.
Smokers considering use of varenicline should
be screened for a history of psychiatric
disorders, have close monitoring, and be
advised to report any adverse effects they
might experience. Care and close surveillance
needs to be taken if prescribing to patients
with psychiatric disorders
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